BACKGROUND: Uterine carcinosarcomas (UCSs) are a rare but clinically aggressive form of cancer. They are biphasic tumors consisting of both epithelial and sarcomatous components. The majority of uterine carcinosarcomas are clonal, with the carcinomatous cells undergoing metaplasia to give rise to the sarcomatous component. The objective of the current study was to identify novel somatically mutated genes in UCSs. METHODS: We whole exome sequenced paired tumor and nontumor DNAs from 14 UCSs and orthogonally validated 464 somatic variants using Sanger sequencing. Fifteen genes that were somatically mutated in at least 2 tumor exomes were Sanger sequenced in another 39 primary UCSs. RESULTS: Overall, among 53 UCSs in the current study, the most frequently mutated of these 15 genes were tumor protein p53 (TP53) (75.5%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (34.0%), protein phosphatase 2, regulatory subunit A, alpha (PPP2R1A) (18.9%), F-box and WD repeat domain containing 7 (FBXW7) (18.9%), chromodomain helicase DNA binding protein 4 (CHD4) (17.0%), and forkhead box A2 (FOXA2) (15.1%). FOXA2 has not previously been implicated in UCSs and was predominated by frameshift and nonsense mutations. One UCS with a FOXA2 frameshift mutation expressed truncated FOXA2 protein by immunoblotting. Sequencing of FOXA2 in 160 primary endometrial carcinomas revealed somatic mutations in 5.7% of serous, 22.7% of clear cell, 9% of endometrioid, and 11.1% of mixed endometrial carcinomas, the majority of which were frameshift mutations. CONCLUSIONS: Collectively, the findings of the current study provide compelling genetic evidence that FOXA2 is a pathogenic driver gene in the etiology of primary uterine cancers, including UCSs. Cancer 2018;124:65-73.
INTRODUCTION
Uterine carcinosarcomas (UCSs), also referred to as malignant mixed M€ ullerian tumors of the uterus, are rare biphasic tumors consisting of both carcinomatous and sarcomatous elements. UCSs have an aggressive clinical course; 1 study reported 5-year relative survival rates of 53.7% at all American Joint Committee on Cancer stages, 73.7% at stage I, 43.3% at stage II, 26.2% at stage III, and 13.6% at stage IV. 1 Although early studies reported that the carcinomatous component determines tumor aggressiveness, 2,3 a recent meta-analysis of 906 UCS cases found that both the carcinoma and sarcoma components can influence prognosis. 4 Molecular studies that analyzed the carcinoma and sarcoma components of individual tumors separately found evidence of shared alterations between each component in a majority of cases. [5] [6] [7] [8] [9] [10] Thus, the majority of UCSs are believed to be monoclonal in origin, resulting from a metaplastic transition of carcinoma cells to sarcoma cells. 11 The carcinoma component often is of serous, clear cell, undifferentiated, high-grade endometrioid, or mixed histology; lower grade endometrioid carcinomas also are observed, although they are less common. 4 The sarcoma component can be of uterine ("homologous") or extrauterine ("heterologous") origin, including rhabdomyosarcoma, chondrosarcoma, or osteosarcoma. 12 Targeted gene sequencing and whole exome sequencing of UCSs have uncovered frequent somatic mutations in genes involved in the DNA damage response ( The objective of the current study was to identify novel somatically mutated genes in UCSs. Herein, we whole-exome sequenced of 14 primary UCSs and paired normal DNAs. Follow-up Sanger sequencing of 15 genes that were mutated in at least 2 discovery screen tumors was performed in another 39 UCSs. Our finding that forkhead box A2 [FOXA2] is somatically mutated in 15.1% of UCSs and is predominated by frameshift and nonsense mutations strongly implicates FOXA2 as a novel pathogenic driver gene in UCSs. We also report frequent FOXA2 mutations in other histological subtypes of endometrial carcinoma (EC), further supporting FOXA2 as a driver of uterine carcinomas.
MATERIALS AND METHODS

Clinical Specimens
The Office of Human Subjects Research at the National Institutes of Health determined that this research was not "human subjects research" as per the Common Rule (45 CFR 46), and therefore no Institutional Review Board review was required for whole exome sequencing or Sanger sequencing of these samples. Anonymized, matched tumor and nontumor (normal) samples sequenced in the discovery and prevalence screen were obtained as fresh frozen tissues from the Cooperative Human Tissue Network (CHTN), which is funded by the National Cancer Institute (NCI) (see Supporting Information Table 1 ). Genomic DNA for 38 UCSs from Washington University in St. Louis, Missouri, (see Supporting Information Table 2 ) also was included in the prevalence screen. EC DNAs included in the current study previously were isolated from 53 serous ECs, 22 clear cell ECs, 67 endometrioid ECs, and 18 mixed histology ECs. [23] [24] [25] Clinical follow-up information was not available for the 15 UCSs obtained from the CHTN or for the 160 ECs in the current study.
Estimation of Neoplastic Cellularity and Genomic DNA Extraction
An H&E section prepared for each frozen tumor specimen received from CHTN was evaluated by a pathologist (M.J.M.) to assess histotype and demark regions of greater than 70% neoplastic cellularity for subsequent DNA isolation (Puregene DNA extraction kit; Qiagen, Valencia, California) (see Supporting Information Table 1 ). Before whole-exome sequencing, 14 paired tumor-normal DNAs were purified further by phenol-chloroform extraction. For cases from Washington University, a gynecologic pathologist performed histologic review of the diagnostic slides from formalin-fixed paraffin-embedded tumor tissue, as well as sections prepared from the fresh-frozen tumor tissue used for DNA isolation (see Supporting Information Table  2 ). Identity testing was performed on all tumor-normal DNA pairs using the Coriell Identity Mapping kit (Coriell Institute for Medical Research, Camden, New Jersey) according to the manufacturer's instructions.
Whole Exome Capture and Sequencing
Sequencing libraries of matched tumor and normal DNAs were generated using the Illumina TruSeqV2:28 capture kit (Illumina Inc, San Diego, California) (see Supporting Information Table 3 ). Enriched libraries were sequenced with the Illumina HiSeq 2000 platform until at least 85% of targeted bases had adequate coverage to produce a most probable genotype score of 10. 26 The average depth of coverage for individual exomes is provided in Supporting Information Table 3 .
Read Mapping, Variant Calling, and Variant Filtering Short sequence reads were aligned to the University of California at Santa Cruz (UCSC) human reference "hg19" using NovoAlign version 2.08.02, and genotypes were called using the program bam2mpg with the -qual_filter 20 option. 26 VarSifter 27 was used to identify coding and splice somatic variants with a most probable genotype (MPG) score 10 in the normal exome, a most probable variant (MPV) score 10 in the tumor exome, and at least 5 reads covering the site in each sample. Single nucleotide variants (SNVs) detected in any normal sample, probable false-positive variants consistent with sequencing artifacts or misaligned reads as determined by manual data curation, and variants annotated as nonclinical SNVs in the Single Nucleotide Polymorphism database (dbSNP; version 135) were filtered out.
Primer Design, Polymerase Chain Reaction Amplification, and Sanger Sequencing Primer sequences and polymerase chain reaction conditions are available on request. Sanger sequencing and analysis were performed as previously described. 25 In the mutation prevalence screen, variant calling was restricted to exonic sequence; splice donor and acceptor sequences were not assessed. Exonic variants were discriminated as somatic or germline by sequencing independent polymerase chain reaction products generated from relevant tumor and matched normal DNAs.
MSI Analysis
MSI analysis of tumor-normal DNA pairs was performed using the Promega MSI Analysis System (version 1.2; Promega Corporation, Madison, Wisconsin), according to the manufacturer's instructions. MSI-high tumor genotypes (2 unstable mononucleotide markers) are reported herein as MSI1. MSI-low (1 unstable mononucleotide marker) and MSI-negative (no unstable mononucleotide markers) tumor genotypes are reported herein as microsatellite stable (MSS).
Cell Lines
The RL-95-2, HEC1A, HEC1B, KLE, and ANC3A EC cell lines were obtained from the American Type Culture Collection or the NCI Developmental Therapeutics Program cell line repository. MFE-280 and MFE-296 were purchased from Sigma-Aldrich (St. Louis, Missouri). HEC-59 was purchased from AddexBio (San Diego, California). Dr. Alessandro A. Santin (Yale University School of Medicine, New Haven, Connecticut) kindly provided the ARK1, ARK2, ARK4, and ARK6 serous EC cell lines; Dr. Bo Rueda (Massachusetts General Hospital, Boston, Massachusetts) kindly provided the SK-UT-2 EC cell line; and Dr. John J. Risinger (Michigan State University, East Lansing, Michigan) kindly provided the NCI-EC2 clear cell EC cell line.
Protein Extraction, Quantification, and Immunoblot Analysis
Protein was extracted from 7 primary UCSs (UCS 1-7) using a protocol modified from Peña-Llopis and Brugarolas. 28 Briefly, tissue was homogenized in 10 volumes of RIPA buffer (Thermo Fisher Scientific, Waltham, Massachusetts) containing complete tablet protease inhibitors (Roche, Nutley, New Jersey), 0.1mM NaVO4, and 1mM NaF (New England BioLabs, Ipswich, Massachusetts). Lysate was centrifuged twice through a QIAshredder column (Qiagen) and then cleared using centrifugation. EC cells were lysed in RIPA buffer (Thermo Fisher Scientific) containing complete tablet protease inhibitors (Roche), 0.1mM NaVO4, and 1mM NaF (New England BioLabs) for 30 minutes on ice and then cleared using centrifugation. Protein was quantified using the Quick Start Bradford reagent (Bio-Rad Laboratories, Hercules, California) and equal amounts of total protein were denatured in LDS sample buffer (Thermo Fisher Scientific) at 808C before sodium dodecyl sulfate-polyacrylamide gel electrophoresis and wet transfer to polyvinylidene fluoride membranes (Bio-Rad). Primary and horseradish peroxidase (HRP)-conjugated secondary antibodies were anti-FOXA2 (#8186; Cell Signaling Technology, Danvers, Massachusetts), b-actin (A2228; Sigma-Aldrich), goat antirabbit HRP (Cell Signaling Technology), and goat antimouse HRP (Cell Signaling Technology).
DNA and RNA Extraction From Frozen Tissue Sections
The following extractions were completed according to the manufacturers' protocols. DNA was extracted from frozen sections that corresponded to regions targeted for protein extraction using the Pinpoint Slide DNA Isolation System (Zymo Research, Orange, California). For tumor UCS-5, RNA was extracted with TRIzol Reagent (Thermo Fisher Scientific) pipetted directly onto the frozen section corresponding to the region used for DNA and protein extraction. RNA was converted to complementary DNA (cDNA) using the Superscript III First strand synthesis kit (Thermo Fisher Scientific).
Accession Code
Whole exome sequencing data have been deposited into the database of Genotypes and Phenotypes (dbGAP), under accession code phs001153.v1.p1.
RESULTS
Mutation Discovery Screen by Whole-Exome Sequencing
Whole-exome sequencing of 14 primary UCS tumornormal pairs achieved an average depth of coverage of 773 for aligned reads. On average, 89.2% of targeted bases had sufficient coverage and quality for variant calling (see Supporting Information Table 3) . After data filtering, we identified 882 exonic (614 nonsynonymous and 268 synonymous) and 21 splice-junction somatic variant calls among the 14 tumors (see Supporting Information Table  4 ). We could orthogonally assess 519 of the nonsynonymous and splice junction variants using Sanger sequencing; 89.4% (464 of 519) of the assessed variants were orthogonally validated as bona fide somatic mutations (448 nonsynonymous and 16 splice-junction mutations) (see Supporting Information Table 4 ). There was a mean of 33 validated nonsynonymous/splice junction somatic mutations per tumor (range 13-71 mutations per tumor); validated mutations were distributed among 426 proteinencoding genes. Seventeen protein-encoding genes, including 6 consensus cancer genes, were somatically mutated in 2 UCS exomes (see Supporting Information Table 4 13 Given the high frequency of frameshift FOXA2 mutations in the prevalence screen tumors (as described below), and the known challenges in calling insertions and deletions by next generation sequencing, 29 we subsequently also Sanger sequenced FOXA2 in the 14 discovery screen tumors.
Among the 53 tumors in the combined discovery and prevalence screens, the most frequently mutated of the 15 genes were TP53 (75.5% of UCSs somatically mutated), PIK3CA (34.0%), PPP2R1A (18.9%), FBXW7 (18.9%), CHD4 (17.0%), and FOXA2 (15.1%) (Fig. 1 Table 5 ) (see Supporting Information Fig. 1) . 13 Of the 6 most frequently mutated genes, FOXA2 is the only gene that, to our knowledge, has not previously been implicated in UCS.
The majority of FOXA2 mutations were frameshift or nonsense mutations predicted to encode truncated proteins that would disrupt 1 functional domains, including the carboxy-terminal transactivation domain (Fig. 2a) ( Table 1) . Two missense mutations in FOXA2 localized to the central DNA binding (Winged helix) domain (Fig.  2a) , which is highly conserved across proteins in the forkhead box family. 30 Both missense mutations are predicted to impact protein function by 3 in silico algorithms (Mutation Assessor, PolyPhen, and SIFT). Only 1 of 8 FOXA2-mutated tumors (1241T; FOXA2-Met142-Profs*8) was MSI1 and none were MSH6-mutated or POLE-mutated (Fig. 1) . 13 In terms of histology, FOXA2 mutations were identified in UCSs for which the sequenced DNA was isolated from admixed carcinoma/ sarcoma (3 cases) or from predominantly carcinoma (5 cases) (see Supporting Information Tables 1 and 2 ).
FOXA2 Is Somatically Mutated in ECs
Because the majority of UCSs are believed to originate from ECs, 11 we extended the current study to Sanger sequence the coding exons of FOXA2 from 160 primary ECs of diverse histotypes (53 serous, 22 clear cell, 67 endometrioid, and 18 mixed). We uncovered somatic FOXA2 mutations in 5.7% of serous ECs, 22.7% of clear cell ECs, 9.0% of endometrioid ECs, and 11.1% of mixed histology ECs (Table 1) . Differences in the mutation frequency of FOXA2 in serous, clear cell, and endometrioid ECs were not found to be statistically significant (P 5 .07, chi-square test). Five frameshift mutations in ECs and 1 frameshift mutation in a UCS formed a FOXA2 mutation cluster, resulting from overlapping genomic deletions in which the first positions of the frameshift were located within amino acids 346 through 349 (Fig.  2b) . All but 1 of 16 FOXA2 mutations in ECs are predicted to prematurely truncate FOXA2 (Fig. 2a) , and the majority of FOXA2-mutated ECs (13 of 16 cases) were microsatellite stable (see Supporting Information Table  6 ), which is consistent with our observations in UCSs (Fig. 1) . 13 
A Recurrent Mutation in FOXA2 Encodes a Truncated Protein
We next sought to evaluate FOXA2 expression in EC cell lines and in primary UCSs. We performed immunoblot analysis for FOXA2 on protein lysates from 14 EC cell lines and 7 primary UCSs. These UCSs lacked matched normal tissue and therefore were not included in our discovery or prevalence mutation screens. Immunoblotting demonstrated variable levels of FOXA2 expression in EC Original Article cell lines (Fig. 3a) (see Supporting Information Fig. 2) . Specifically, FOXA2 protein expression was readily detected in 7 of 14 EC cell lines, including 3 of 4 serous EC cell lines (ARK2, ARK4, and ARK6) (Fig. 3a) ; the single clear cell EC cell line evaluated (NCI-EC-2) expressed lower levels of FOXA2 (see Supporting Information Fig.  2) . Three of the 7 primary UCSs assessed by immunoblot analysis had readily detectable FOXA2 protein expression (Fig. 3b) . Strikingly, one tumor (UCS-5) exhibited a shorter form of FOXA2 than expected (Fig. 3b) ; sequencing all coding exons of FOXA2 from the genomic DNA of this tumor revealed that it harbored the A346Gfs*11 variant (Fig. 3c) . Matched normal DNA for UCS-5 was not available for sequencing but we predict that the A346Gfs*11 variant in this tumor is more likely to be somatic than germline because this alteration also occurred as a somatic mutation in a serous EC in the current study (Table 1) , and because it occurred within the recurrently mutated N-terminal region of FOXA2 (Fig.  2) . Although the A346Gfs*11 variant in UCS-5 appeared to be heterozygous at the genomic level, only the variant allele was detectable in cDNA generated from this tumor (Fig. 3c) . No FOXA2 exonic sequence variants were detected within the genomic DNA of UCS-1, UCS-2, UCS-4, UCS-6, or UCS-7; UCS-3 was not sequenced.
DISCUSSION
UCSs are rare gynecologic malignances that are associated with a poor clinical outcome. [1] [2] [3] Using a combination of whole exome sequencing and targeted Sanger sequencing, the results of the current study demonstrate that the FOXA2 (HNF3B) "pioneer" forkhead transcription factor, which has established roles in uterine glandular epithelium development and uterine biology, [31] [32] [33] [34] [35] undergoes frequent somatic mutations in UCSs. The occurrence of FOXA2 mutations in 15.1% of UCSs in the current study coupled with the fact that they are predominated by frameshift mutations predicted to prematurely truncate FOXA2 strongly suggest they are pathogenic driver mutations in some UCSs. FOXA2 recently was proposed to be 2558T  1643T  1698T  199T  190T  201T  194T  1965T  2215T  2465T  189T  1828T  203T  1208T  1596T  193T  195T  200T  2073T  1467T  1689T  1939T  1949T  1630T  1850T  2250T  1895T  2087T  2486T  1595T  1115T  1690T  1728T  1241T  1144T  1239T  188T  2031T  2111T  2416T  1203T 1413T 1765T a tumor suppressor gene in endometrioid ECs. 36 Our observation of FOXA2 mutations in 9% of endometrioid ECs corroborates the recent report of FOXA2 mutations in 9.4% of such tumors. 36 We extended these observations to further implicate FOXA2 as a candidate driver gene in other EC histological subtypes: within our cohort, 22 .7% of clear cell, 11.1% of mixed histology, and 5.7% of serous ECs were found to harbor FOXA2 mutations.
The FOXA2 transcription factor has 3 major functional domains: an N-terminal transactivation domain (residues 1-52), a central winged-helix DNA binding domain (residues 157-257), and a C-terminal transactivation domain. All somatic frameshift/nonsense mutations we uncovered in UCSs and ECs are predicted to encode truncated proteins lacking the C-terminal transactivation domain. 25% of somatic frameshift/nonsense mutations identified in the current study (4 of 20 mutations) are predicted to also disrupt the central wingedhelix DNA-binding domain, and another 35% (7 of 20 mutations) are initiated in the N-terminal forkhead region.
The genomic DNA sequences of the majority of FOXA2-mutated tumors in the current study also had evidence of a wild type allele. One UCS that exhibited wildtype and mutated FOXA2 in genomic DNA had only the mutated allele in the cDNA and exhibited only a truncated protein by immunoblot analysis. These observations suggest that this tumor is either homozygous for the mutated allele with the wild type allele in the genomic DNA being contributed by admixed normal cells that do not express the FOXA2 protein, or that the tumor is heterozygous at the genomic level but expresses FOXA2 exclusively from the mutant allele. Further studies are required to determine whether other FOXA2-mutated UCSs and ECs exclusively express the mutant allele.
TP53, PIK3CA, and PPP2R1A were found to be somatically mutated in 75.5%, 34.0%, and 18.9%, respectively, of the current study cohort of 53 UCSs. These genes previously were sequenced by targeted nextgeneration sequencing in 36 UCSs included in the current study but matched normal DNAs were not evaluated. 13 By Sanger sequencing these 3 genes, we found 43 of 46 variants reported by McConechy et al 13 to be somatic, and we identified 9 additional somatic mutations that were not previously noted among the 36 UCSs (see Supporting Information Table 7) .
Our combined whole exome sequencing and targeted gene sequencing of UCSs also identified frequent somatic mutations in FBXW7 and CHD4. The incidence of somatic FBXW7 mutations among the UCSs in the current study (18.9%) is in keeping with the frequency at which this tumor suppressor gene is reported to be mutated in other UCS cohorts (10.7%-39%). 5, 8, 20, 21 All FBXW7 mutations in the UCSs within the current study localized to the substrate-binding WD repeats (see Supporting Information Fig. 1 ), which is consistent with the FBXW7 mutation spectrum in other cancers, 37, 38 including ECs. 25, 39 We first nominated CHD4 as a candidate cancer gene based on mutational observations we made in ECs. 25 Our finding that 17% of UCSs had somatically mutated CHD4, which encodes a catalytic subunit of the NuRD chromatin remodeling complex, is in keeping with recent reports of CHD4 mutations in 5.9% to 18% of UCS cohorts. 5, 8, 19 The majority of CHD4 mutations in the current study (6 of 10 mutations) were localized to the catalytic ATPase-helicase and helicase domains (see Supporting Information Fig. 1) , and 2 of these mutations involved arginine-975 and arginine-1162, which are prominent pan-cancer mutation hotspots in CHD4. 40, 41 Using a combination of whole exome sequencing and targeted gene sequencing, we identified a high frequency of FOXA2 frameshift mutations in UCSs. In addition, we also identified frequent FOXA2 frameshift mutations in uterine carcinomas, including serous ECs and clear cell ECs. Collectively, these findings lead us to nominate FOXA2 as a pathogenic driver gene in some of the most clinically aggressive forms of uterine cancer.
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